In combination with dynamic network biomarker (DNB) score analysis, the study has identified disease‐progression associated CD8+CD27+CXCR3− T cell signatures, with great potential in accurately predicting the progression of SLE and in providing crucial guidance on clinical treatment options. This evidence concerns the gene CXCR3 and systemic lupus erythematosus.